Non-Hodgkin's Lymphoma Clinical Trial
Official title:
Feasibility Study of R-CHOP Plus Bevacizumab in Patients With Diffuse Large B Cell Lymphoma (DLBCL)
This study evaluates the use of the standard treatment R-CHOP plus the anti-VEGF drug, bevacizumab and whether this treatment is feasible in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL).
Non-Hodgkin's lymphoma is increasing in incidence with more than 287,000 cases world-wide
and 9000 cases in UK diagnosed each year. DLBCL is the most frequently occurring NHL,
constituting approximately 31% of all non-Hodgkin's lymphomas.
Rituximab-CHOP chemotherapy has shown clinical efficacy and is regarded as standard
treatment in patients with DLBCL. NICE has recently approved the use of rituzimab in
combination with CHOP for all newly diagnosed patients with DLBCL stage II-IV.
Angiogenesis plays an important role in the pathophysiology of both solid tumours and
hematologic malignancies. Vascular endothelial growth factor (VEGF) is the most important
pro-angiogenic factor involved in normal and pathologic angiogenesis and studies have also
implicated VEGF in lymphomagenesis. Elevated VEGF gene expression correlates with diffuse
large B cell lymphoma subtypes of poor prognosis on microarray analysis. In patients with
lymphoma, high circulating serum VEGF levels have been strongly associated with poor
clinical outcomes independent of other predictive factors.
Bevacizumab is a humanized monoclonal antibody that binds to VEGF thus preventing binding to
its receptors thus inhibiting the downstream pathways dependent on receptor stimulation.
Bevacizamab has shown activity in solid tumours (colorectal, renal, breast and non-small
cell lung cancer) and early results suggest that the combination of R-CHOP plus bevacizamab
is feasible in patients with non Hodgkin's lymphoma.
Patients will be treated with a minimum of 6 cycles of treatment. A further 2 cycles, to a
total of 8 cycles, may be administered if continuing response to treatment has been
documented but residual disease is still detectable on restaging after 6 cycles. Each cycle
of treatment is 21 days.
Follow up - a) Clinic visit with physical examination at 3, 6, 9, 12, 18 and 24 months after
completion of R-CHOP-B, then annually.
b) CT scan of chest, abdomen and pelvis at 3 months and 1 year after finishing treatment.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
| Completed |
NCT04152148 -
A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients
|
Phase 1 | |
| Recruiting |
NCT05191225 -
Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study
|
Phase 4 | |
| Recruiting |
NCT05096234 -
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05623982 -
Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03664635 -
MB-CART20.1 Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
| Terminated |
NCT01699581 -
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT01763398 -
Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study
|
N/A | |
| Completed |
NCT01205503 -
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
|
Phase 2 | |
| Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
| Completed |
NCT00969462 -
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
|
Phase 4 | |
| Completed |
NCT00659425 -
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Terminated |
NCT00475332 -
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
|
Phase 2 | |
| Completed |
NCT00533728 -
Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT00577161 -
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
|
Phase 3 | |
| Completed |
NCT00608907 -
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
|
Phase 1 | |
| Completed |
NCT00581646 -
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
|
N/A | |
| Completed |
NCT00430352 -
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
|
Phase 4 |